Calvenza⢠-03 EIV/EHV - Boehringer Ingelheim Vetmedica
Calvenza⢠-03 EIV/EHV - Boehringer Ingelheim Vetmedica
Calvenza⢠-03 EIV/EHV - Boehringer Ingelheim Vetmedica
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Calvenza <br />
-<strong>03</strong> <strong>EIV</strong>/<strong>EHV</strong><br />
Equine Rhinopneumonitis-Influenza Killed Virus Vaccine<br />
Description<br />
Calvenza -<strong>03</strong> <strong>EIV</strong>/<strong>EHV</strong> is an<br />
Equine Rhinopneumonitis-Influenza<br />
Killed Virus Vaccine.<br />
Features<br />
Incorporates the latest emerging North<br />
American <strong>EIV</strong> strain (Ohio/20<strong>03</strong>), as<br />
well as an established North American<br />
<strong>EIV</strong> strain (Kentucky/2/95).<br />
Also incorporates a relevant Eurasian<br />
<strong>EIV</strong> strain (Newmarket/2/93).<br />
Unique <strong>EHV</strong>-1 equine respiratory<br />
origin isolate.<br />
Stimulates antibody to <strong>EHV</strong>-1 &<br />
<strong>EHV</strong>-4.<br />
Novel adjuvant.<br />
Safe, all killed vaccine.<br />
Includes innovative pliable nasal<br />
applicator.<br />
Benefits<br />
Flexible dose administration.<br />
Three dose regimen conforms to<br />
AAEP recommendations.<br />
No reversion to virulence concern.<br />
Minimal vaccine site reactions.<br />
Dosage & Administration<br />
Using aseptic technique inoculate<br />
horses IM with a 2 mL dose. Administer<br />
a second 2 mL dose IM in 3-4<br />
weeks using a different injection site.<br />
Administer a third 2 mL dose in 3-4<br />
weeks either IM or IN. Revaccinate<br />
annually and prior to anticipated<br />
exposure either IM or IN.<br />
Precautions<br />
Store at a temperature between<br />
35° - 45° F (2° - 7° C). Protect<br />
from freezing. Shake well before<br />
using. Do not vaccinate within<br />
21 days of slaughter.<br />
Antidote: Epinephrine.<br />
Highlights<br />
• First killed virus vaccine<br />
to include the latest North<br />
American strain to be<br />
identified (Ohio/20<strong>03</strong>).<br />
• Relevant types, quantities of<br />
<strong>EIV</strong> & <strong>EHV</strong> antigens with a<br />
novel adjuvant.<br />
• Flexible routes of<br />
administration.<br />
• Safe for use in pregnant<br />
mares.<br />
Uses<br />
For the vaccination of healthy, susceptible<br />
horses 6 months of age or<br />
older, including pregnant mares, as<br />
an aid in the reduction of respiratory<br />
disease due to equine herpesvirus type<br />
1 (<strong>EHV</strong>-1) and type 4 (<strong>EHV</strong>-4) and by<br />
equine influenza type A 2<br />
.<br />
Warning<br />
This product has been tested under<br />
laboratory conditions and shown to<br />
meet all Federal standards for safety<br />
and efficacy in normal, healthy,<br />
immunocompetent animals. This level<br />
of performance may be affected by<br />
conditions such as stress, weather,<br />
nutrition, disease, parasitism, other<br />
treatments, individual idiosyncrasies<br />
or impaired immunological competency.<br />
These factors should be<br />
considered by the user when<br />
evaluating product performance or<br />
freedom from reactions.<br />
Product Information<br />
Name Code Size<br />
Calvenza -<strong>03</strong> 132-615 2 mL<br />
<strong>EIV</strong>/<strong>EHV</strong><br />
1 dose<br />
132-625 20 mL<br />
10 doses
Equine<br />
Rhinopneumonitis-<br />
Influenza Vaccine<br />
Killed Virus<br />
Calvenza-<strong>03</strong> <strong>EIV</strong>/<strong>EHV</strong><br />
1Dose/2 mL<br />
Indications: Forthevaccination of healthy, susceptible<br />
horses 6 months of ageorolder, includingpregnant mares,<br />
as an aid in the reduction of respiratory diseases caused by<br />
equine herpesvirus type 1 (<strong>EHV</strong>-1) andtype4(<strong>EHV</strong>-4),and<br />
by equine influenza virustypes A2 North American andA2<br />
Eurasian.<br />
Administrationand Dosage: Shake wellbefore use. Using<br />
aseptic technique,inoculate horses intramuscularly with a<br />
2mLdose. Administerasecond 2mLdoseintramuscularlyin<br />
3-4weeks usingadifferent injection site. Administer a third<br />
2mLdosein3-4weeksby either the intramuscular or intranasalroute.<br />
Revaccinate annuallyand prior to anticipated<br />
exposure, by either the intramuscularor intranasalroute.<br />
For Veterinary UseOnly<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong><strong>Vetmedica</strong>,Inc.<br />
St.Joseph, MO 64506<br />
U.S. VeterinaryLicense No.124<br />
Code 132-615<br />
abcd<br />
Precautions: Store at 35–45°F (2–7°C). Protectfromfreezing. Do not vaccinate<br />
within 21 days before slaughter.Anaphylactoid reactions mayoccur followinguse.<br />
Antidote: Epinephrine.<br />
This producthas been tested underlaboratoryconditions andshown to meetall<br />
Federal standards for safety andefficacy in normal, healthy,immunocompetent<br />
animals. This level ofperformancemay be affected by conditions suchasstress,<br />
weather, nutrition,disease,parasitism,other treatments,individual idiosyncrasies,<br />
or impaired immunological competency. Thesefactorsshouldbeconsidered by<br />
the userwhenevaluatingproductperformance or freedomfromreactions.<br />
Preservative: Gentamicin.<br />
<strong>Boehringer</strong> <strong>Ingelheim</strong> <strong>Vetmedica</strong>, Inc.<br />
2621 North Belt Highway • St. Joseph, MO 64506-2002<br />
Information 800-325-9167 • Sales Service 800-325-9167 • Fax 816-236-2717<br />
www.bi-vetmedica.com<br />
BI 1326-<strong>03</strong> 02/08
Change language